Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Director · Chief Executive Officer | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kymera Therapeutics, Inc.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 666,568 |
Ending reported balance
After 2026-10-01 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 30,000 · Balance 696,568 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. Row 2 · 2026-10-01 · Sale · Disposed 3,525 · Balance 693,043 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.93 to $111.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-10-01 · Sale · Disposed 5,506 · Balance 687,537 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.97 to $112.92 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-10-01 · Sale · Disposed 4,876 · Balance 682,661 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.95 to $113.88 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-10-01 · Sale · Disposed 7,601 · Balance 675,060 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.94 to $114.91 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2026-10-01 · Sale · Disposed 8,230 · Balance 666,830 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.94 to $115.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2026-10-01 · Sale · Disposed 262 · Balance 666,568 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.16 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2029-11-13 | Direct | 60,000 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 30,000 · Balance 60,000 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F8: The shares underlying this stock option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.93 to $111.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.97 to $112.92 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.95 to $113.88 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.94 to $114.91 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.94 to $115.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.16 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The shares underlying this stock option are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2025 Filed Sep 16, 2025 20:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 30,000 | $2.08 | $62,400.00 |
DisclosureSEC source: 0001193125-25-204997 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 690,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-25-081199 · ownership.xml · derivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 465,559 Underlying: Common Stock · 30,000 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F3 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 30,000 | $49.00 | $1,470,000.00 |
DisclosureSEC source: 0000950170-25-081199 · ownership.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 660,482 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 30,000 | $2.08 | $62,400.00 |
DisclosureSEC source: 0000950170-25-081199 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 690,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. F2 · balance_after: This number includes 523 shares acquired under the Registrant's employee stock purchase plan on June 2, 2025. Read SEC document |
| March 03, 2025 Filed Mar 3, 2025 23:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 365,000 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0000950170-25-031145 · ownership.xml · derivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,000 Underlying: Common Stock · 365,000 shares Expires 2035-03-02 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 12:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-25-004549 · ownership.xml · derivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 495,559 Underlying: Common Stock · 10,000 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option vested in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 12:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 10,000 | $2.08 | $20,800.00 |
DisclosureSEC source: 0000950170-25-004549 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 659,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2024 Filed Jul 1, 2024 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,773 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0000950170-24-079666 · ownership.xml · derivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,456 Underlying: Common Stock · 18,773 shares Expires 2030-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of May 14, 2020, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| July 01, 2024 Filed Jul 1, 2024 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 18,773 | $5.33 | $100,060.09 |
DisclosureSEC source: 0000950170-24-079666 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 649,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 12:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,413 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-24-075332 · ownership.xml · derivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 505,559 Underlying: Common Stock · 14,413 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 12:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 14,413 | $2.08 | $29,979.04 |
DisclosureSEC source: 0000950170-24-075332 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 631,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes 1,203 shares acquired under the Registrant's employee stock purchase plan on June 1, 2024. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 530,000 | $0.00 Strike: $43.50 | $0.00 |
DisclosureSEC source: 0000950170-24-025085 · ownership.xml · derivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 530,000 Underlying: Common Stock · 530,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| January 02, 2024 Filed Jan 2, 2024 22:43 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-24-000386 · ownership.xml · derivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519,972 Underlying: Common Stock · 9,000 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| January 02, 2024 Filed Jan 2, 2024 22:43 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 9,000 | $2.08 | $18,720.00 |
DisclosureSEC source: 0000950170-24-000386 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 615,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,632 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-23-059580 · ownership.xml · derivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 528,972 Underlying: Common Stock · 17,632 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,368 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-23-059580 · ownership.xml · derivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,368 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 17,632 | $2.08 | $36,674.56 |
DisclosureSEC source: 0000950170-23-059580 · ownership.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 606,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 2,368 | $2.08 | $4,925.44 |
DisclosureSEC source: 0000950170-23-059580 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 588,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2023 Filed Aug 8, 2023 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-23-039894 · ownership.xml · derivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,368 Underlying: Common Stock · 12,000 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this stock option vested in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| August 08, 2023 Filed Aug 8, 2023 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 12,000 | $2.08 | $24,960.00 |
DisclosureSEC source: 0000950170-23-039894 · ownership.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 586,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes 870 shares acquired under the Registrant's employee stock purchase plan on May 31, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:31 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $32.07 | $0.00 |
DisclosureSEC source: 0000899243-23-006986 · doc4.xml · derivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2033-02-28 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| December 08, 2022 Filed Dec 8, 2022 23:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-038010 · doc4.xml · derivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,725 Underlying: Common Stock · 10,000 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| December 08, 2022 Filed Dec 8, 2022 23:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 10,000 | $2.08 | $20,800.00 |
DisclosureSEC source: 0000899243-22-038010 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 573,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes 1,769 shares acquired under the Registrant's employee stock purchase plan on December 1, 2022. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 00:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,676 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-033709 · doc4.xml · derivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 546,604 Underlying: Common Stock · 27,676 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 00:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 32,056 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-033709 · doc4.xml · derivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,368 Underlying: Common Stock · 32,056 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 00:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 27,676 | $2.08 | $57,566.08 |
DisclosureSEC source: 0000899243-22-033709 · doc4.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 00:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 32,056 | $2.08 | $66,676.48 |
DisclosureSEC source: 0000899243-22-033709 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 3, 2022 23:27 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-016431 · doc4.xml · derivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,424 Underlying: Common Stock · 20,000 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| May 03, 2022 Filed May 3, 2022 23:27 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 20,000 | $2.08 | $41,600.00 |
DisclosureSEC source: 0000899243-22-016431 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 502,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:31 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 275,100 | $0.00 Strike: $38.53 | $0.00 |
DisclosureSEC source: 0000899243-22-009081 · doc4.xml · derivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,100 Underlying: Common Stock · 275,100 shares Expires 2032-02-29 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2022, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| January 14, 2022 Filed Jan 14, 2022 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-002022 · doc4.xml · derivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,424 Underlying: Common Stock · 10,000 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| January 14, 2022 Filed Jan 14, 2022 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 10,000 | $2.08 | $20,800.00 |
DisclosureSEC source: 0000899243-22-002022 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 482,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,612 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · derivative · entry 17 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 574,280 Underlying: Common Stock · 8,612 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 241 | $53.97 | $13,006.77 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · nonDerivative · entry 14 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,623 | $53.27 | $86,457.21 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · nonDerivative · entry 13 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,440 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.88 to $53.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 4,022 | $52.02 | $209,209.56 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · nonDerivative · entry 12 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,063 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.60 to $52.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,726 | $51.31 | $139,877.06 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · nonDerivative · entry 11 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,085 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.60 to $51.575. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 8,612 | $2.08 | $17,912.96 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · nonDerivative · entry 10 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,923 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · derivative · entry 16 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 582,892 Underlying: Common Stock · 16,923 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 347 | $55.05 | $19,103.36 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · nonDerivative · entry 9 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.05 to $55.06. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 6,644 | $54.42 | $361,582.43 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · nonDerivative · entry 8 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,546 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.01 to $54.995. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 9,932 | $53.68 | $533,109.04 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · nonDerivative · entry 7 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479,190 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.01 to $54.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 16,923 | $2.08 | $35,199.84 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · nonDerivative · entry 6 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,465 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · derivative · entry 15 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 599,815 Underlying: Common Stock · 22,465 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| January 10, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 106 | $54.99 | $5,828.94 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · nonDerivative · entry 5 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. Read SEC document |
| January 10, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 4,201 | $54.40 | $228,545.32 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · nonDerivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,305 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.99 to $54.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 10, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 10,673 | $53.35 | $569,378.93 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,506 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.99 to $53.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 10, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 7,485 | $52.46 | $392,643.64 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,179 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.99 to $52.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 10, 2022 Filed Jan 13, 2022 00:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 22,465 | $2.08 | $46,727.20 |
DisclosureSEC source: 0000899243-22-001807 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2021 Filed Dec 16, 2021 21:49 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-048614 · doc4.xml · derivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,424 Underlying: Common Stock · 8,000 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.